Você procurou por: pbo (Inglês - Eslovaco)

pbo
0, 42

pbo +
pbo + dmard

pbo + mtx
jsn - zúženie kĺbovej štrbiny * - p ≤ 0, 0001, tcz oproti pbo + mtx ** - p < 0, 005, tcz oproti pbo + mtx

bao and pbo
bao a pbo

pbo + dmar d
pbo + dmard

pbo tcz pbo tcz
mtx

pbo + mtx/ dmard
tcz - tocilizumab mtx - metotrexát pbo - placebo dmard - antireumatikum modifikujúce priebeh choroby * - p < 0, 05, tcz oproti pbo + mtx/ dmard ** - p < 0, 01, tcz oproti pbo + mtx/ dmard *** - p < 0, 0001, tcz oproti pbo + mtx/ dmard

with placebo (pbo).
physician global assessment)

tcz mtx tcz pbo tcz pbo tcz
tcz pbo 8 mg/ kg + mtx + mtx

determination of the combination bao + pbo
stanovenie kombinácie bao + pbo

tcz mtx tcz pbo tcz pbo tcz pbo + tcz
tcz 8 mg/ kg + dmard

p < 0.0001; t12/pr compared to pbo/pr48.
p < 0,0001; t12/pr v porovnaní s pbo/pr48.

table 15 shows the response rates for the t12/pr48 and the pbo/pr48 arms.
tabuľka 15 znázorňuje podiely odpovedí pre ramená t12/pr48 a pbo/pr48.

pbo/pr: placebo for 12 weeks with peginterferon alfa-2a and ribavirin for 48 weeks
pbo/pr: placebo počas 12 týždňov s peginterferónom alfa-2a a ribavirínom počas 48 týždňov

p < 0.001 for ustekinumab 45 mg or 90 mg in comparison with placebo (pbo).
p < 0,001 pre 45 mg alebo 90 mg ustekinumabu v porovnaní s placebom (pbo).

pbo/pr48: placebo for 16 weeks in combination with peginterferon alfa-2a and ribavirin for 48 weeks
pbo/pr48: placebo počas 16 týždňov v kombinácii s peginterferónom alfa-2a a ribavirínom počas 48 týždňov

for the purposes of subheadings 701322, 701333, 701341 and 701391, the expression ‘lead crystal’ means only glass having a minimum lead monoxide (pbo) content by weight of 24 %.
na účely podpoložiek 701322, 701333, 701341 a 701391 termín „olovnatý krištáľ“ znamená len sklo s obsahom oxidu olovnatého (pbo) najmenej 24 % hmotnosti.